Home Cart Sign in  
Chemical Structure| 182349-12-8 Chemical Structure| 182349-12-8

Structure of Rupatadine Fumarate
CAS No.: 182349-12-8

Chemical Structure| 182349-12-8

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

Rupatadine fumarate is an inhibitor of PAFR and histamine (H1) receptor with Ki of 550 nM and 102 nM, respectively.

Synonyms: UR-12592 Fumarate; Rupatadine (fumarate)

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of Rupatadine Fumarate

CAS No. :182349-12-8
Formula : C30H30ClN3O4
M.W : 532.03
SMILES Code : CC1=CN=CC(CN2CC/C(CC2)=C3C4=CC=C(Cl)C=C4CCC5=CC=CN=C5\3)=C1.O=C(O)/C=C/C(O)=O
Synonyms :
UR-12592 Fumarate; Rupatadine (fumarate)
MDL No. :MFCD00926499
InChI Key :JYBLCDXVHQWMSU-WLHGVMLRSA-N
Pubchem ID :6449107

Safety of Rupatadine Fumarate

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302-H315-H319-H335
Precautionary Statements:P261-P305+P351+P338

Related Pathways of Rupatadine Fumarate

GPCR

Isoform Comparison

Biological Activity

Target
  • H1 receptor

    Histamine H1 receptor, Ki:102 nM

Clinical Trial:

NCT Number Conditions Phases Recruitment Completion Date Locations
NCT00199238 URTICARIA PHASE2 TERMINATED 2004-09-27 Hospital Saint Louis, Paris Ce... More >>dex 10, 75475, France Less <<

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

1.88mL

0.38mL

0.19mL

9.40mL

1.88mL

0.94mL

18.80mL

3.76mL

1.88mL

Dissolving Methods
Please choose the appropriate dissolution scheme according to your animal administration guide.For the following dissolution schemes, clear stock solution should be prepared according to in vitro experiments, and then cosolvent should be added in turn:

in order to ensure the reliability of the experimental results, the clarified stock solution can be properly preserved according to the storage conditions; The working fluid for in vivo experiment is recommended to be prepared now and used on the same day;

The percentage shown in front of the following solvent refers to the volume ratio of the solvent in the final solution; If precipitation or precipitation occurs in the preparation process, it can be assisted by heating and/or ultrasound.
Protocol 1
Protocol 2

References

[1]Queralt M, Brazis P, et al. In vitro inhibitory effect of rupatadine on histamine and TNF-alpha release from dispersed canine skin mast cells and the human mast cell line HMC-1. Inflamm Res. 2000 Jul;49(7):355-60.

[2]Merlos M, Giral M, et al. Rupatadine, a new potent, orally active dual antagonist of histamine and platelet-activating factor (PAF). J Pharmacol Exp Ther. 1997 Jan;280(1):114-21.

[3]Nettis E, Delle Donne P, Di Leo E, Calogiuri GF, Ferrannini A, Vacca A. Rupatadine for the treatment of urticaria. Expert Opin Pharmacother. 2013 Sep;14(13):1807-13

[4]González-Núñez V, Bachert C, Mullol J. Rupatadine: global safety evaluation in allergic rhinitis and urticaria. Expert Opin Drug Saf. 2016 Oct;15(10):1439-48

[5]Mullol J, Bousquet J, Bachert C, Canonica GW, Giménez-Arnau A, Kowalski ML, Simons FE, Maurer M, Ryan D, Scadding G. Update on rupatadine in the management of allergic disorders. Allergy. 2015 Jan;70 Suppl 100:1-24

[6]Abajian M, Curto-Barredo L, Krause K, Santamaria E, Izquierdo I, Church MK, Maurer M, Giménez-Arnau A. Rupatadine 20 mg and 40 mg are Effective in Reducing the Symptoms of Chronic Cold Urticaria. Acta Derm Venereol. 2016 Jan;96(1):56-9

[7]Malavige GN, Wijewickrama A, Fernando S, Jeewandara C, Ginneliya A, Samarasekara S, Madushanka P, Punchihewa C, Paranavitane S, Idampitiya D, Wanigatunga C, Dissanayake H, Prathapan S, Gomes L, Aman SAB, John AS, Ogg GS. A preliminary study on efficacy of rupatadine for the treatment of acute dengue infection. Sci Rep. 2018 Mar 1;8(1):3857

 

Historical Records

Categories